- Home
- UL vs GILD Comparison
UL vs GILD Comparison
Compare UL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UL
- GILD
- Stock Information
- Founded
- UL 1930
- GILD 1987
- Country
- UL United Kingdom
- GILD United States
- Employees
- UL N/A
- GILD N/A
- Industry
- UL Package Goods/Cosmetics
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UL Consumer Discretionary
- GILD Health Care
- Exchange
- UL Nasdaq
- GILD Nasdaq
- Market Cap
- UL 136.3B
- GILD 113.0B
- IPO Year
- UL N/A
- GILD 1992
- Fundamental
- Price
- UL $55.68
- GILD $91.84
- Analyst Decision
- UL Buy
- GILD Buy
- Analyst Count
- UL 5
- GILD 26
- Target Price
- UL $60.00
- GILD $98.17
- AVG Volume (30 Days)
- UL 2.5M
- GILD 6.6M
- Earning Date
- UL 02-06-2025
- GILD 02-11-2025
- Dividend Yield
- UL 3.42%
- GILD 3.35%
- EPS Growth
- UL N/A
- GILD N/A
- EPS
- UL 2.82
- GILD 0.10
- Revenue
- UL $64,601,950,064.00
- GILD $28,299,000,000.00
- Revenue This Year
- UL $2.91
- GILD $6.50
- Revenue Next Year
- UL $3.40
- GILD $0.36
- P/E Ratio
- UL $19.46
- GILD $908.39
- Revenue Growth
- UL N/A
- GILD 3.31
- 52 Week Low
- UL $46.46
- GILD $62.07
- 52 Week High
- UL $65.87
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- UL 38.68
- GILD 51.58
- Support Level
- UL $54.60
- GILD $90.82
- Resistance Level
- UL $56.43
- GILD $93.07
- Average True Range (ATR)
- UL 0.59
- GILD 1.54
- MACD
- UL -0.02
- GILD -0.03
- Stochastic Oscillator
- UL 35.25
- GILD 56.28
About UL Unilever PLC
Unilever is a diversified personal-care (52% of 2022 sales by value), homecare (14%), and packaged food (34%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Axe and Dove skin products, and the TRESemmé haircare brand. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, Garancia, and The Vegetarian Butcher.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).